Dr. Readon called the results "historic".
Here is my key takeaway. Last sentence is key:
Financial guidance: Celldex expects that its cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through 2017, however, this could be impacted by our clinical data results from the RINTEGA program and their potential impact on our pace of commercial manufacturing and the rate of expansion of our commercial operations.
Nice call on CRIS Frank. Do you have a L/T target price? Stock reminds me of ASTX before it was bought out. ASTX had a better pipeline but both had a royalty stream.
Looks like Oppy had about 15.4% of the firm as of 12/31/14. Still have not seen who might have caused all the heavy trading in late Jan 15. Remember the 13M share day?